These results were further extended by the EPHESUS trial (Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study) in heart failure patients after myocardial infarction [55] and the EMPHASIS-HF trial (Eplerenone in Mild Patients Hospitalization And Survival Study in Heart Failure) in patients with NYHA class II HFrEF [56], both trials showed that the MR antagonist eplerenone, in addition to standard therapy, caused a highly substantial decrease in mortality and heart failure hospitalizations in those individuals. Here, NR3C2 is linked to heart failure.